Skip to main content
CCTG NE2 (STOPNET) neuroendocrine study has officially open in Canada.

CCTG NE2 neuroendocrine study has opened in Canada

The CCTG NE2 STOPNET neuroendocrine study has officially open in Canada. Researchers are investigating whether somatostatin analogues (SSA) are needed after targeted therapy for patients with neuroendocrine tumours.

“NE2 addresses an important question for patients and the healthcare system of whether we can reduce treatment burden by stopping SSAs after PRRT has been completed,” says Dr Jonathan Loree, the NE2 study co-chair and BC Cancer Oncologist.

More >>
 
 CCTG CE9 (LUMOS2) now enrolling Canadian patients.

International brain cancer study CE9 (LUMOS2) now enrolling Canadian patients

CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.

More >>
 
Canadian researchers will test a promising new fecal microbiota treatment on patients to cure advanced melanoma

Canadian researchers will test a promising new fecal microbiota treatment on patients to cure advanced melanoma

ME17 one of the world’s largest randomized controlled clinical trials using fecal microbiota transplantation (FMT) to improve the effectiveness of the standard of care for advanced melanoma.

More >>
 

Planned trials

ALC9

Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

BLC6

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

BR38

Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

HE2

SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma

MD1

CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)

ME17

LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma

PAC5

Lanreotide for the Prevention of Postoperative Pancreatic Fistula

PR26

Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)

SC30

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT

SC31

Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)

SRC8

Doxorubicin + Pembrolizumab vs Doxorubicin for Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Recently activated

AL6

MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

More >>

ALC7

Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials

More >>

ALC8

Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

More >>

BR36

CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer

More >>

CE9

Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)

More >>

ES3

NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)

More >>

HN13

Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer

More >>

MAC30

Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score More >>

NE2

STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Tumours

More >>

PM2

Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated with Immuno-Oncotherapeutics (CAN-IMPACT-IO)

More >>

PR25

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes

More >>

SC29

Stereotactic Body Radiotherapy (SBRT) vs Conventional Palliative Radiotherapy (CRT) for Participants with Painful Non-Spine Bone Metastases

More >>

VU2

STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study

More >>
Welcome to Patient Representative Michelle Audoin

Welcome to Patient Representative Michelle Audoin

Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.

More >>
 
Patient Representative Suzanne Wood

Welcome to Patient Representative Suzanne Wood

CCTG would like to extend a warm welcome to Patient Representative Suzanne Wood who will be supporting the GI disease site committee. Suzanne is from Toronto and was diagnosed with Stage IV Colon cancer in July 2022.

More >>
 
Welcoming new Patient Representative Haydn Bechthold

Welcoming new Patient Representative Haydn Bechthold

CCTG would like to welcome our new Patient Representative Haydn Bechthold who will be supporting the Gastrointestinal Disease Site Committee.

More >>
 
Welcome to Patient Representative Jasmine Heuring

Welcome to Patient Representative Jasmine Heuring

A very warm welcome to Jasmine Heuring who has joined the CCTG Patient Representatives Committee and will be supporting the Adolescents & Young Adults and Sarcoma Disease Site Committees. Jasmine is from Winnipeg Manitoba and is a cancer advocate and healthcare analyst.

More >>
 

Publications

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

N Engl J Med 388: 2159 - 2170, 2023
Eskander RN;Sill MW;Beffa L;Moore RG;Hope JM;Musa FB;Mannel R;Shahin MS;Cantuaria GH;Girda E;Mathews C;Kavecansky J;Leath CA;Gien LT;Hinchcliff EM;Lele SB;Landrum LM;Backes F;O'Cearbhaill RE;Al Baghdadi T;Hill EK;Thaker PH;John VS;Welch S;Fader AN;Powell MA;Aghajanian C;

More >>

Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial (ONLINE)

International Journal of Radiation Oncology*Biology*Physics , 2023
Petersen PM;Cook AD;Sydes MR;Clarke N;Cross W;Kynaston H;Logue J;Neville P;Payne H;Parmar MKB;Parulekar W;Persad R;Saad F;Stirling A;Parker CC;Catton C;

More >>

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial (ONLINE)

The Oncol , 2023
Gupta A;Hay AE;Crump M;Djurfeldt MS;Zhu L;Cheung MC;Shepherd LE;Chen BE;Booth CM;

More >>

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

N Engl J Med 388: 1645 - 1656, 2023
Partridge AH;Niman SM;Ruggeri M;Peccatori FA;Azim HA;Colleoni M;Saura C;Shimizu C;Sætersdal AB;Kroep JR;Mailliez A;Warner E;Borges VF;Amant F;Gombos A;Kataoka A;Rousset-Jablonski C;Borstnar S;Takei J;Lee JE;Walshe JM;Ruíz-Borrego M;Moore HCF;Saunders C;Bjelic-Radisic V;Susnjar S;Cardoso F;Smith KL;Ferreiro T;Ribi K;Ruddy K;Kammler R;El-Abed S;Viale G;Piccart M;Korde LA;Goldhirsch A;Gelber RD;Pagani O;

More >>

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Cancers 15: 1823, 2023
Karamouza E;Glasspool RM;Kelly C;Lewsley LA;Carty K;Kristensen GB;Ethier JL;Kagimura T;Yanaihara N;Cecere SC;You B;Boere IA;Pujade-Lauraine E;Ray-Coquard I;Proust-Lima C;Paoletti X;

More >>

Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6

Supportive Care in Cancer 31: 256, 2023
Mian H;Ringash J;Meyer R;Hay AE;Shepherd L;Djurfeldt M;Winter JN;Sussman J;Pater J;Chen BE;Prica A;

More >>